Bright Angel Therapeutics
Matthew Carlyle was appointed Executive Vice President in February, 2020 and Chief Financial Officer in May, 2017. Mr. Carlyle brings extensive experience and relationships across global biotechnology and venture capital to adMare, having been a partner of a national venture capital firm, CFO of a publicly traded biotech, and CFO of a number of private life sciences companies.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Bright Angel Therapeutics
Bright Angel Therapeutics is a developer of novel therapeutics designed to provide treatment of drug-resistant and life-threatening fungal infections. The company's services increases efficacy of current treatments and eradicates drug resistance by targeting the stress responses required by fungi for survival, virulence and drug resistance,enabling users to overcome the frequent emergence of clinical resistance largely responsible for the severe morbidity and mortality associated with infection by diverse fungal pathogens.